Want to see AU:ACR full AI Analyst Report?
ACR Stock Chart & Stats
AU$0.01
>-AU$0.01(-8.33%)
At close: 4:00 PM EDT
AU$0.01
>-AU$0.01(-8.33%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume169.96K
Average Volume (3M)120.95K
Market Cap
AU$5.90M
Enterprise ValueAU$8.72M
Total Cash (Recent Filing)AU$946.00K
Total Debt (Recent Filing)AU$3.64M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding589,677,800
10 Day Avg. Volume76,863
30 Day Avg. Volume120,955
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.51
Price to Sales (P/S)4.73
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$14.20M
Bulls Say, Bears Say
Bulls Say
High Revenue GrowthSustained, large revenue increases demonstrate durable market traction and product adoption that can compound over time. If management maintains unit economics, this growth supports operating leverage, expands addressable market presence, and creates a clearer path to fixed-cost absorption and eventual profitability.
Gross Margin ImprovementA dramatic gross margin improvement signals a structurally stronger cost-to-revenue profile or higher-value pricing for core products. High gross margins provide durable operating leverage, giving room to cover R&D and SG&A and improving the company’s ability to reach sustainable operating profits if revenue growth persists.
Improving Free Cash Flow TrendA year-over-year improvement in free cash flow growth suggests the company is starting to convert revenue into more usable cash. This trend, if sustained, reduces reliance on external financing, eases liquidity strain, and supports reinvestment in commercial expansion or R&D over the medium term.
Bears Say
High LeverageVery high debt-to-equity materially increases financial risk, creating persistent interest costs and refinancing exposure. With limited cash generation, leverage constrains strategic flexibility, raises default risk in adverse conditions, and may force costly capital raises or cutbacks that impair long-term growth plans.
Negative Operating Cash FlowOngoing negative operating cash flow indicates the business is not yet self-sustaining and must rely on external capital to fund operations. Over months this weakens liquidity, increases dilution or debt needs, and curtails the company’s ability to consistently fund R&D, commercialization, or scale without structural improvements.
Persistent Losses & Negative MarginsContinued net losses and negative EBIT margins show underlying cost structure or scaling inefficiencies. Until profitability drivers (cost control, pricing, or sustained higher-margin revenue) are realized, losses will erode equity, depress returns, and likely require external financing that can dilute shareholders or constrain strategic choices.
Acrux News
ACR FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is AU$5.90M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Aug 21, 2026 which is in 13 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of AU$0.06 which represents an annual dividend yield of N/A. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 589,677,800 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in AU:ACR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:ACR Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-34.57%
Trailing 12-Months
Company Description
Acrux Limited
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―